Cognitive Science, LLC was founded by Michael R. Drapp (CEO) and Daniel Babcock (President) to provide leading-edge research, consulting and integrated product development for the analysis and treatment of Alzheimer’s, Mild Cognitive Impairment (MCI) and related cognitive degenerative diseases.
Utilizing commercially available technologies, in combination with pharmacological therapy (if prescribed), Cognitive Science’s approach exploits the emerging Internet of Things (IOT) and Big Data as vehicles for broad-scale patient analysis and treatment.
Michael and Dan recognized the need for a scalable patient care and treatment architecture that is not currently available. While current patient care typically concentrates on relieving the symptoms of the underlying cognitive disease, very little is being done to provide a holistic approach to decelerate and/or reverse the degenerative processes.
Conflicting patient and research data have dampened all but the most direct and individualized patient care approaches; leading in some cases to an escalation of the degenerative disease while simply masking the patient’s symptoms. Cognitive Science’s approach concentrates more fully on the underlying disease while still providing best-practices control of the patient’s symptoms.
By delaying the onset of Alzheimer’s disease, or retarding its rapid advancement, the gap between a productive lifestyle and longevity is narrowed.
Cognitive Science has developed methodologies that significantly narrow this productivity gap in most patients. Until a cure is found, or a strong pharmacological solution developed and tested, Cognitive Science’s approach is the best available suite of treatment alternatives available today.